Global Adrenocortical Carcinoma Drugs Market Insights, Forecast to 2029

Publication ID:

PB504232671

Publication Date:

June 1, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 4,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The adrenocortical carcinoma drugs market has recorded the development of several advanced imaging techniques, which are non-invasive and exhibit enhanced diagnostic accuracy in the detection of adrenal lesions.
Market Analysis and Insights: Global Adrenocortical Carcinoma Drugs Market
The global Adrenocortical Carcinoma Drugs market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
For instance, unenhanced computed tomography adrenal densitometry is used to differentiate adrenal adenomas from malignant lesions based on the presence of intracellular lipids. A combination of positron emission tomography/computed tomography is also gaining popularity among end-users for the identification of malignant and benign lesions. Similarly, multiphase computed tomography technique is being used to calculate absolute and relative percentage washout, and thereby, differentiate between benign and malignant lesions.
Report Includes
This report presents an overview of global market for Adrenocortical Carcinoma Drugs market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Adrenocortical Carcinoma Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Adrenocortical Carcinoma Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Adrenocortical Carcinoma Drugs revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Adrenocortical Carcinoma Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Adrenocortical Carcinoma Drugs revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Bristol-Myers Squibb Co., Eli Lilly and Co., Laboratoire HRA Pharma SAS, Progenics Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd., etc.
By Company
Bristol-Myers Squibb Co.
Eli Lilly and Co.
Laboratoire HRA Pharma SAS
Progenics Pharmaceuticals Inc.
Teva Pharmaceutical Industries Ltd.
Segment by Type
Chemotherapy
Targeted therapy
Segment by Application
Hospital
Research institute
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Adrenocortical Carcinoma Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Adrenocortical Carcinoma Drugs companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Adrenocortical Carcinoma Drugs revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adrenocortical Carcinoma Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Chemotherapy
1.2.3 Targeted therapy
1.3 Market by Application
1.3.1 Global Adrenocortical Carcinoma Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Research institute
1.3.4 Clinic
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Adrenocortical Carcinoma Drugs Market Perspective (2018-2029)
2.2 Global Adrenocortical Carcinoma Drugs Growth Trends by Region
2.2.1 Adrenocortical Carcinoma Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Adrenocortical Carcinoma Drugs Historic Market Size by Region (2018-2023)
2.2.3 Adrenocortical Carcinoma Drugs Forecasted Market Size by Region (2024-2029)
2.3 Adrenocortical Carcinoma Drugs Market Dynamics
2.3.1 Adrenocortical Carcinoma Drugs Industry Trends
2.3.2 Adrenocortical Carcinoma Drugs Market Drivers
2.3.3 Adrenocortical Carcinoma Drugs Market Challenges
2.3.4 Adrenocortical Carcinoma Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Adrenocortical Carcinoma Drugs by Players
3.1.1 Global Adrenocortical Carcinoma Drugs Revenue by Players (2018-2023)
3.1.2 Global Adrenocortical Carcinoma Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Adrenocortical Carcinoma Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Adrenocortical Carcinoma Drugs, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Adrenocortical Carcinoma Drugs Market Concentration Ratio
3.4.1 Global Adrenocortical Carcinoma Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adrenocortical Carcinoma Drugs Revenue in 2022
3.5 Global Key Players of Adrenocortical Carcinoma Drugs Head office and Area Served
3.6 Global Key Players of Adrenocortical Carcinoma Drugs, Product and Application
3.7 Global Key Players of Adrenocortical Carcinoma Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Adrenocortical Carcinoma Drugs Breakdown Data by Type
4.1 Global Adrenocortical Carcinoma Drugs Historic Market Size by Type (2018-2023)
4.2 Global Adrenocortical Carcinoma Drugs Forecasted Market Size by Type (2024-2029)
5 Adrenocortical Carcinoma Drugs Breakdown Data by Application
5.1 Global Adrenocortical Carcinoma Drugs Historic Market Size by Application (2018-2023)
5.2 Global Adrenocortical Carcinoma Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Adrenocortical Carcinoma Drugs Market Size (2018-2029)
6.2 North America Adrenocortical Carcinoma Drugs Market Size by Type
6.2.1 North America Adrenocortical Carcinoma Drugs Market Size by Type (2018-2023)
6.2.2 North America Adrenocortical Carcinoma Drugs Market Size by Type (2024-2029)
6.2.3 North America Adrenocortical Carcinoma Drugs Market Share by Type (2018-2029)
6.3 North America Adrenocortical Carcinoma Drugs Market Size by Application
6.3.1 North America Adrenocortical Carcinoma Drugs Market Size by Application (2018-2023)
6.3.2 North America Adrenocortical Carcinoma Drugs Market Size by Application (2024-2029)
6.3.3 North America Adrenocortical Carcinoma Drugs Market Share by Application (2018-2029)
6.4 North America Adrenocortical Carcinoma Drugs Market Size by Country
6.4.1 North America Adrenocortical Carcinoma Drugs Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Adrenocortical Carcinoma Drugs Market Size by Country (2018-2023)
6.4.3 North America Adrenocortical Carcinoma Drugs Market Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Adrenocortical Carcinoma Drugs Market Size (2018-2029)
7.2 Europe Adrenocortical Carcinoma Drugs Market Size by Type
7.2.1 Europe Adrenocortical Carcinoma Drugs Market Size by Type (2018-2023)
7.2.2 Europe Adrenocortical Carcinoma Drugs Market Size by Type (2024-2029)
7.2.3 Europe Adrenocortical Carcinoma Drugs Market Share by Type (2018-2029)
7.3 Europe Adrenocortical Carcinoma Drugs Market Size by Application
7.3.1 Europe Adrenocortical Carcinoma Drugs Market Size by Application (2018-2023)
7.3.2 Europe Adrenocortical Carcinoma Drugs Market Size by Application (2024-2029)
7.3.3 Europe Adrenocortical Carcinoma Drugs Market Share by Application (2018-2029)
7.4 Europe Adrenocortical Carcinoma Drugs Market Size by Country
7.4.1 Europe Adrenocortical Carcinoma Drugs Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Adrenocortical Carcinoma Drugs Market Size by Country (2018-2023)
7.4.3 Europe Adrenocortical Carcinoma Drugs Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Adrenocortical Carcinoma Drugs Market Size (2018-2029)
8.2 China Adrenocortical Carcinoma Drugs Market Size by Type
8.2.1 China Adrenocortical Carcinoma Drugs Market Size by Type (2018-2023)
8.2.2 China Adrenocortical Carcinoma Drugs Market Size by Type (2024-2029)
8.2.3 China Adrenocortical Carcinoma Drugs Market Share by Type (2018-2029)
8.3 China Adrenocortical Carcinoma Drugs Market Size by Application
8.3.1 China Adrenocortical Carcinoma Drugs Market Size by Application (2018-2023)
8.3.2 China Adrenocortical Carcinoma Drugs Market Size by Application (2024-2029)
8.3.3 China Adrenocortical Carcinoma Drugs Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Adrenocortical Carcinoma Drugs Market Size (2018-2029)
9.2 Asia Adrenocortical Carcinoma Drugs Market Size by Type
9.2.1 Asia Adrenocortical Carcinoma Drugs Market Size by Type (2018-2023)
9.2.2 Asia Adrenocortical Carcinoma Drugs Market Size by Type (2024-2029)
9.2.3 Asia Adrenocortical Carcinoma Drugs Market Share by Type (2018-2029)
9.3 Asia Adrenocortical Carcinoma Drugs Market Size by Application
9.3.1 Asia Adrenocortical Carcinoma Drugs Market Size by Application (2018-2023)
9.3.2 Asia Adrenocortical Carcinoma Drugs Market Size by Application (2024-2029)
9.3.3 Asia Adrenocortical Carcinoma Drugs Market Share by Application (2018-2029)
9.4 Asia Adrenocortical Carcinoma Drugs Market Size by Region
9.4.1 Asia Adrenocortical Carcinoma Drugs Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Adrenocortical Carcinoma Drugs Market Size by Region (2018-2023)
9.4.3 Asia Adrenocortical Carcinoma Drugs Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Adrenocortical Carcinoma Drugs Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Adrenocortical Carcinoma Drugs Market Size by Type
10.2.1 Middle East, Africa, and Latin America Adrenocortical Carcinoma Drugs Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Adrenocortical Carcinoma Drugs Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Adrenocortical Carcinoma Drugs Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Adrenocortical Carcinoma Drugs Market Size by Application
10.3.1 Middle East, Africa, and Latin America Adrenocortical Carcinoma Drugs Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Adrenocortical Carcinoma Drugs Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Adrenocortical Carcinoma Drugs Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Adrenocortical Carcinoma Drugs Market Size by Country
10.4.1 Middle East, Africa, and Latin America Adrenocortical Carcinoma Drugs Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Adrenocortical Carcinoma Drugs Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Adrenocortical Carcinoma Drugs Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Bristol-Myers Squibb Co.
11.1.1 Bristol-Myers Squibb Co. Company Details
11.1.2 Bristol-Myers Squibb Co. Business Overview
11.1.3 Bristol-Myers Squibb Co. Adrenocortical Carcinoma Drugs Introduction
11.1.4 Bristol-Myers Squibb Co. Revenue in Adrenocortical Carcinoma Drugs Business (2018-2023)
11.1.5 Bristol-Myers Squibb Co. Recent Developments
11.2 Eli Lilly and Co.
11.2.1 Eli Lilly and Co. Company Details
11.2.2 Eli Lilly and Co. Business Overview
11.2.3 Eli Lilly and Co. Adrenocortical Carcinoma Drugs Introduction
11.2.4 Eli Lilly and Co. Revenue in Adrenocortical Carcinoma Drugs Business (2018-2023)
11.2.5 Eli Lilly and Co. Recent Developments
11.3 Laboratoire HRA Pharma SAS
11.3.1 Laboratoire HRA Pharma SAS Company Details
11.3.2 Laboratoire HRA Pharma SAS Business Overview
11.3.3 Laboratoire HRA Pharma SAS Adrenocortical Carcinoma Drugs Introduction
11.3.4 Laboratoire HRA Pharma SAS Revenue in Adrenocortical Carcinoma Drugs Business (2018-2023)
11.3.5 Laboratoire HRA Pharma SAS Recent Developments
11.4 Progenics Pharmaceuticals Inc.
11.4.1 Progenics Pharmaceuticals Inc. Company Details
11.4.2 Progenics Pharmaceuticals Inc. Business Overview
11.4.3 Progenics Pharmaceuticals Inc. Adrenocortical Carcinoma Drugs Introduction
11.4.4 Progenics Pharmaceuticals Inc. Revenue in Adrenocortical Carcinoma Drugs Business (2018-2023)
11.4.5 Progenics Pharmaceuticals Inc. Recent Developments
11.5 Teva Pharmaceutical Industries Ltd.
11.5.1 Teva Pharmaceutical Industries Ltd. Company Details
11.5.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.5.3 Teva Pharmaceutical Industries Ltd. Adrenocortical Carcinoma Drugs Introduction
11.5.4 Teva Pharmaceutical Industries Ltd. Revenue in Adrenocortical Carcinoma Drugs Business (2018-2023)
11.5.5 Teva Pharmaceutical Industries Ltd. Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Bristol-Myers Squibb Co.
Eli Lilly and Co.
Laboratoire HRA Pharma SAS
Progenics Pharmaceuticals Inc.
Teva Pharmaceutical Industries Ltd.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂